

September 10, 2010



## UPDATE: Stellar Biotechnologies Files Key Patent for Company

PT. HUENEME, CA -- (MARKET WIRE) -- 09/10/10 -- Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.

John Sundsmo, Ph.D., VP Research and Intellectual Property, said, "With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates."

Corporate Website: [www.StellarBiotechnologies.com](http://www.StellarBiotechnologies.com)

Stellar News at Marketwire: <http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788>

About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) - ([www.StellarBiotechnologies.com](http://www.StellarBiotechnologies.com)): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

Darrell Brookstein

Executive VP, Business Development & Finance

[dbrookstein@stellariotech.com](mailto:dbrookstein@stellariotech.com)

